Systemic Immune-Inflammation Index Is Superior to Neutrophil to Lymphocyte Ratio in Prognostic Assessment of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Biomed Res Int. 2020 Dec 18:2020:7961568. doi: 10.1155/2020/7961568. eCollection 2020.

Abstract

Results: SII, NLR, and PLR did not define patient groups with distinct clinicopathological characteristics. SII, NLR, and PLR cut-off values were 547, 2.13, and 88.23, as determined by ROC analysis; the corresponding areas under the curve (AUCs) were 0.625, 0.555, and 0.571, respectively. Cox regression models identified SII as independently associated with OS. Patients with low SII had prolonged OS (65 vs. 41 months, P = 0.017, HR: 3.24, 95% CI: 1.23-8.55). In the Z test, the difference in AUC between SII and NLR was statistically significant (Z = 2.721, 95% CI: 0.0194-0.119, P = 0.0065).

Conclusion: Our study suggests that the pretreatment SII value is significantly correlated with OS in breast cancer patients undergoing NAC and that the prognostic utility of SII is superior to that of NLR and PLR.

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Area Under Curve
  • Breast Neoplasms / blood
  • Breast Neoplasms / diagnosis*
  • Breast Neoplasms / drug therapy*
  • Female
  • Humans
  • Immune System
  • Inflammation
  • Kaplan-Meier Estimate
  • Lymphocytes / cytology*
  • Middle Aged
  • Neoadjuvant Therapy / methods*
  • Neutrophils / cytology*
  • Prognosis
  • Proportional Hazards Models
  • ROC Curve
  • Regression Analysis
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Antineoplastic Agents